HRSA's July 2026 request for information on training clinicians and delivering psychedelic therapy in community health centers, if a psychedelic drug is ever FDA-approved — 59 comments filed before the August 13 deadline.
HRSA sits inside the Department of Health and Human Services and funds the country’s network of community health centers, the clinics that serve roughly 32 million patients a year, many in rural areas or without other access to care. On July 14, 2026, HRSA published “Training and Care Delivery Models for Safe Administration of Potential FDA-Approved Psychedelic Therapies in Ambulatory Clinical Settings,” a Request for Information filed in the Federal Register under docket number 2026-14146.
A Request for Information is not a proposed rule. HRSA is not asking whether to allow psychedelic therapy or proposing language for a regulation; it is gathering ideas before any of that groundwork exists. The premise stated in the notice is explicitly conditional: if the FDA approves a psychedelic drug product for a mental health indication, how should the federally funded safety-net clinic system be ready to deliver it. No psychedelic drug has FDA approval as of this guide’s last review, so the RFI is contingency planning, not implementation.
The notice organizes its questions into three groups.
HRSA asked for input on training standards for the clinicians involved at each stage of a psychedelic-assisted session: pre-dosing (screening and preparatory counseling), in-clinic administration (monitoring the patient through the dosing session itself), and post-administration (integration support afterward). Each phase implies a different staffing model: screening leans on intake clinicians, in-session monitoring needs someone credentialed to manage a multi-hour visit, and integration overlaps with existing behavioral-health staffing HRSA-funded clinics already run.
The second group of questions targets the specific clinic types HRSA funds: Federally Qualified Health Centers, Certified Community Behavioral Health Clinics, and Rural Health Clinics. These sites already operate on thin margins with existing behavioral-health staffing gaps, so the real question is whether a clinic that cannot currently fill a psychiatric nurse practitioner role could staff a multi-hour supervised dosing session at all, not just whether psychedelic therapy works clinically in a research setting.
The third area asks about technology, including AI applications, as a way to stretch a small pool of specially trained staff across more patients and more locations. The notice does not specify what that would look like in practice. Remote monitoring during a portion of a session, AI-assisted screening or intake triage, and centralized supervision of multiple sites are all plausible reads of a deliberately open-ended question.
The RFI traces to Executive Order 14401, “Accelerating Medical Treatments for Serious Mental Illness,” which the President signed April 18, 2026. The order cites more than 14 million American adults living with a serious mental illness and directs federal health agencies to speed up research, review, and preparation for new treatment options, psychedelic therapies among them. HHS and the VA separately signed a memorandum of understanding under the same order covering veteran access and clinician training; HRSA’s RFI is the piece of that broader push aimed at the civilian safety-net clinic system rather than the VA system.
HRSA received 59 comments before the docket closed August 13, 2026, ranging from short paragraphs to submissions running 20-plus pages. Commenters included psychedelic drug developers such as Definium Therapeutics (formerly MindMed) and the Association for Prescription Psychedelics, a trade coalition of drug developers formed in late 2024 to push for FDA-approved access; care-delivery companies building clinic networks around a future approval; operators already licensed under Oregon’s and Colorado’s state psychedelic programs; advocacy and nonprofit groups; professional associations; and clinician training providers. Recurring themes across the submissions centered on credentialing and licensing requirements for the staff who would administer therapy, the physical and staffing infrastructure a clinic would need, program costs, and how any of it could scale to HRSA’s network of underserved sites without pricing those clinics out entirely.
Because Oregon and Colorado already run licensed psilocybin programs outside the FDA-approval track, several commenters had real operating data to point to rather than pure speculation, a distinction the FDA’s own September hearing notice draws too, in treating state-program outcome data as useful evidence even while excluding state-program policy advocacy from its scope. Our own legal-status-by-state tracker shows that gap directly: Oregon and Colorado are the only two states with a live, regulated facilitator pathway today, which is exactly why their operators were positioned to answer HRSA’s cost and staffing questions with real numbers instead of estimates.
The RFI does not approve any drug, propose a regulation, set a timeline for a rule, or commit HRSA to funding anything. Nothing in it changes the Schedule I status of psilocybin, MDMA, or any other psychedelic under the Controlled Substances Act, and it does not create a legal pathway to receive psychedelic therapy at a community health center today. Comments HRSA received are not binding, and the agency has not published a response summary, a proposed rule, or a stated timeline for either as of this guide’s last review.
For what is legally available right now, see our guide to what psychedelics are legal in the US and the legal status by state tool.
Community health centers and their clinicians gain an early signal of what HRSA is thinking about for workforce standards, well before any funding or credentialing requirement exists. A clinic administrator planning ahead has more reason to track this RFI than to act on it yet.
Existing facilitators and training programs in Oregon and Colorado are the closest thing to a real-world credentialing model HRSA has to draw on. See our Oregon facilitator certification guide and MDMA therapist training programs guide for what that training actually costs and requires today, independent of anything HRSA eventually decides.
Patients in underserved areas are the RFI’s stated focus, but they are also the furthest from anything changing: this is infrastructure planning for a drug approval that has not happened, layered on top of a clinic system already short-staffed for the behavioral health services it provides now.
It's a Request for Information the Health Resources and Services Administration published on July 14, 2026, asking the public how community health centers should train clinicians and deliver psychedelic therapy if the FDA ever approves a psychedelic drug product. It is not a rule, and it does not approve, schedule, or legalize anything on its own.
August 13, 2026. HRSA had not announced a rulemaking timeline or published a response summary as of this guide's last review.
No. Every substance under discussion remains Schedule I federally. The RFI is HRSA planning ahead for a scenario, FDA approval of a psychedelic drug product, that has not happened yet. Planning for delivery infrastructure is a separate track from FDA's approval decision and any later DEA rescheduling action.
Clinician workforce training across the pre-dosing, in-clinic administration, and post-administration phases of a psychedelic therapy session; care-delivery models for Federally Qualified Health Centers, Certified Community Behavioral Health Clinics, and Rural Health Clinics; and technology-enabled scalability, including AI applications, for stretching a scarce, specially trained workforce across underserved areas.
HRSA received 59 comments from a mix of drug developers, care-delivery companies, state-regulated Oregon and Colorado facilitators and operators, advocacy and nonprofit groups, professional associations, and clinician training providers.
Our legalization tracker follows FDA milestones, executive orders, state bills, and DEA scheduling actions, updated automatically.
Get HRSA Psychedelic Therapy Workforce RFI updates
New votes, rules, court rulings, and access changes for HRSA Psychedelic Therapy Workforce RFI — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.